Table 1.
Demographics and baseline clinical features in good and poor sleepers.
| Cohort | Good sleepers | Poor sleepers | p-value* | |
|---|---|---|---|---|
| (n = 109) | (n = 50) | (n = 59) | ||
| Age at baseline visit, year | 66.0 ± 9.1† | 65.7 ± 10.1 | 66.2 ± 8.1 | 0.80 |
| Male gender, n (%) | 67 (61.5) | 32 (64.0) | 35 (59.3) | 0.38 |
| Education, year | 11.3 ± 4.2 | 11.9 ± 3.8 | 10.8 ± 4.3 | 0.11 |
| Disease duration, months | 6.0 ± 3.5 | 6.4 ± 3.8 | 5.7 ± 3.1 | 0.97 |
| LEDD, mg/d | 227.3 ± 178.7 | 202.7 ± 182.2 | 233.2 ± 175.1 | 0.19 |
| MDS-UPDRS Part III | 20.3 ± 9.7 | 19.7 ± 9.1 | 20.1 ± 9.8 | 0.60 |
| H & Y stage | 1.9 ± 0.4 | 1.8 ± 0.4 | 1.8 ± 0.4 | 0.52 |
| MoCA | 26.1 ± 2.7 | 26.3 ± 2.5 | 25.9 ±2.9 | 0.48 |
*
Two independent samples t-test or Mann-Whitney U test for continuous variables (depending on normality assumption), and Chi-square test for categorical variables.
†
Continuous variables reported as mean ± standard deviation; categorical variables reported as frequency (%).
LEDD, Levodopa equivalent daily dosage; MDS-UPDRS, Movement Disorders Society Unified Parkinson's Disease Rating Scale; H & Y Stage, Hoehn and Yahr stage; MoCA, Montreal Cognitive Assessment; PD-MCI, Parkinson's Disease mild cognitive impairment.